検索:
徳島大学大学院医歯薬学研究部医学域先端臨床医学教育研究プロジェクト
徳島大学大学院医歯薬学研究部医学域医科学部門内科系血液・内分泌代謝内科学
徳島大学病院診療科内科血液内科
徳島大学研究クラスター群研究クラスター群 (登録)1804024 HTLV-1ウイルスの感染伝播抑制と難治性腫瘍成人T細胞白血病/リンパ腫に対する新規治療法の開発
徳島大学医学部医学科生体制御医学講座血液・内分泌代謝学分野
徳島大学研究クラスター群研究クラスター群 (重点)1803003 リード薬の構造展開による新規阻害薬の創出とその物性・治療活性の最適化
(researchmapへのインポート用ファイル) [PDF解説] [researchmapへの自動反映について]

研究活動

個人のホームページ

専門分野

血液学 (Hematology)

研究テーマ

(多発性骨髄腫)

著書・論文

著書:

1. 賀川 久美子, 前田 悠作, 大浦 雅博, 曽我部 公子, 藤野 ひかる, 髙橋 真美子, 丸橋 朋子, 岩佐 昌美, 宇高 憲吾, 原田 武志, 伊勢 孝之, 藤井 志朗, 中村 信元, 三木 浩和, 八木 秀介, 竹内 恭子, 尾崎 修治, 安倍 正博, 藤野 ひかる :
治療後長期生存が得られた心不全合併ALアミロイドーシス症例の検討,
臨床血液, 2017年10月.
(DOI: 10.11406/rinketsu.58.2197,   CiNii: 130006246890)

学術論文(審査論文):

1. Mohannad Ashtar, Hirofumi Tenshin, Jumpei Teramachi, Ariunzaya Bat-Erdene, Masahiro Hiasa, Asuka Oda, Kotaro Tanimoto, Sou Shimizu, Yoshiki Higa, Takeshi Harada, Masahiro Oura, Kimiko Sogabe, Shingen Nakamura, Shiroh Fujii, Ryohei Sumitani, Hirokazu Miki, Kengo Udaka, Mamiko Takahashi, Kumiko Kagawa, Itsuro Endo, Eiji Tanaka, Toshio Matsumoto and Masahiro Abe :
The Roles of ROS Generation in RANKL-Induced Osteoclastogenesis: Suppressive Effects of Febuxostat.,
Cancers, Vol.12, No.4, 2020.
(徳島大学機関リポジトリ: 115041,   DOI: 10.3390/cancers12040929,   PubMed: 32283857)
2. Teru Hideshima, Daisuke Ogiya, Jiye Liu, Takeshi Harada, Keiji Kurata, Jooeun Bae, Walter Massefski and Kenneth C. Anderson :
Immunomodulatory drugs activate NK cells via both Zap-70 and cereblon-dependent pathways,
Leukemia, Vol.in press, No.in press, inpress, 2020.
(DOI: 10.1038/s41375-020-0809-x,   PubMed: 32238854,   Elsevier: Scopus)
3. Udaka Kengo, Shingen Nakamura, Shiroh Fujii, Ryosuke Miyamoto, Matsui Naoko, Kawata Shiyori, Hori Taiki, Murai Junpei, Sumitani Ryohei, Masahiro Oura, Kimiko Sogabe, Takahashi Mamiko, Takeshi Harada, Kumiko Kagawa, Yuishin Izumi, Masahiro Abe and Miki Hirokazu :
Successful treatment of progressive multifocal leukoencephalopathy with mirtazapine and mefloquine in refractory myeloma,
International Journal of Myeloma, Vol.10, No.1, 8-12, 2020.
4. Matthew Ho, Tianzeng Chen, Jiye Liu, Paul Dowling, Teru Hideshima, Li Zhang, Eugenio Morelli, Gulden Camci-Unal, Xinchen Wu, Yu-Tzu Tai, Kenneth Wen, Mehmet Samur, Robert L. Schlossman, Ralph Mazitschek, Emma L. Kavanagh, Sinead Lindsay, Takeshi Harada, Amanda McCann, Kenneth C. Anderson, Peter O'Gorman and Giada Bianchi :
Targeting histone deacetylase 3 (HDAC3) in the bone marrow microenvironment inhibits multiple myeloma proliferation by modulating exosomes and IL-6 trans-signaling,
Leukemia, Vol.34, No.1, 196-209, 2020.
(DOI: 10.1038/s41375-019-0493-x,   PubMed: 31142847,   Elsevier: Scopus)
5. Shuji Ozaki, Takeshi Harada, Hikaru Yagi, Etsuko Sekimoto, Hironobu Shibata, Toshio Shigekiyo, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki, Kumiko Kagawa and Masahiro Abe :
Polyclonal Immunoglobulin Recovery after Autologous Stem Cell Transplantation Is an Independent Prognostic Factor for Survival Outcome in Patients with Multiple Myeloma,
Cancers, Vol.12, No.1, 12, 2019.
(徳島大学機関リポジトリ: 115047,   DOI: 10.3390/cancers12010012,   PubMed: 31861479,   Elsevier: Scopus)
6. Masami Iwasa, Takeshi Harada, Asuka Oda, Ariunzaya Bat-Erdene, Jumpei Teramachi, Hirofumi Tenshin, Mohannad Ashtar, Masahiro Oura, Kimiko Sogabe, Kengo Udaka, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki, Kumiko Kagawa, Shuji Ozaki and Masahiro Abe :
PD-L1 upregulation in myeloma cells by panobinostat in combination with interferon-γ.,
Oncotarget, Vol.10, No.20, 1903-1917, 2019.
(徳島大学機関リポジトリ: 113359,   DOI: 10.18632/oncotarget.26726,   PubMed: 30956773,   Elsevier: Scopus)
7. 宮上 侑子, 中村 信元, 大浦 雅博, 岡本 惠暢, 高橋 真美子, 曽我部 公子, 岩佐 昌美, 原田 武志, 藤井 志朗, 三木 浩和, 賀川 久美子, 上原 久典, 安倍 正博 :
不明熱と著明な高CRP血症で発症したde novo CD20陰性びまん性大細胞型B細胞リンパ腫の1例,
四国医学雑誌, Vol.74, No.5-6, 193-200, 2018年.
(徳島大学機関リポジトリ: 112987,   CiNii: 120006552370)
8. Ariunzaya Bat-Erdene, Shingen Nakamura, Asuka Oda, Masami Iwasa, Jumpei Teramachi, Mohannad Ashtar, Takeshi Harada, Hirokazu Miki, Hirofumi Tenshin, Masahiro Hiasa, Shiroh Fujii, Kimiko Sogabe, Masahiro Oura, Kengo Udaka, Kumiko Kagawa, Sumiko Yoshida, Ken-ichi Aihara, Kiyoe Kurahashi, Itsuro Endo and Masahiro Abe :
Class 1 HDAC and HDAC6 inhibition inversely regulates CD38 induction in myeloma cells via interferon-α and ATRA.,
British Journal of Haematology, 2018.
(徳島大学機関リポジトリ: 113393,   DOI: 10.1111/bjh.15673,   PubMed: 30474853,   Elsevier: Scopus)
9. Anamaria Gulla, Teru Hideshima, Giada Bianchi, MT Fulciniti, M Samur Kemal, J Qi, Yu-Tzu Tai, Takeshi Harada, E Morelli, N Amodio, R Carrasco, P Tagliaferri, NC Munshi, P Tassone and C. Kenneth Anderson :
Protein arginine methyltransferase 5 has prognostic relevance and is a druggable target in multiple myeloma,
Leukemia, Vol.32, No.4, 996-1002, 2018.
(DOI: 10.1038/leu.2017.334,   PubMed: 29158558,   Elsevier: Scopus)
10. Shiroh Fujii, Shingen Nakamura, Asuka Oda, Hirokazu Miki, Hirofumi Tenshin, Jumpei Teramachi, Masahiro Hiasa, Ariunzaya Bat-Erdene, Yusaku Maeda, Masahiro Oura, Mamiko Takahashi, Masami Iwasa, Itsuro Endo, Sumiko Yoshida, Ken-ichi Aihara, Kiyoe Kurahashi, Takeshi Harada, Kumiko Kagawa, Michiyasu Nakao, Shigeki Sano and Masahiro Abe :
Unique anti-myeloma activity by thiazolidine-2,4-dione compounds with Pim inhibiting activity.,
British Journal of Haematology, Vol.180, No.2, 246-258, 2018.
(徳島大学機関リポジトリ: 112752,   DOI: 10.1111/bjh.15033,   PubMed: 29327347,   Elsevier: Scopus)
11. Hiroto Ohguchi, Takeshi Harada, Morihiko Sagawa, Shohei Kikuchi, YT Tai, PG Richardson, Teru Hideshima and KC Anderson :
KDM6B modulates MAPK pathway mediating multiple myeloma cell growth and survival,
Leukemia, Vol.31, No.12, 2661-2669, 2017.
(DOI: 10.1038/leu.2017.141,   PubMed: 28487543,   Elsevier: Scopus)
12. Takeshi Harada, Ohguchi Hiroto, Grondin Yohann, Kikuchi Shohei, Sagawa Morihiko, Tai Yu-Tzu, Mazitschek Ralph, Hideshima Teru and Anderson C. Kenneth :
HDAC3 regulates DNMT1 expression in multiple myeloma: therapeutic implications,
Leukemia, Vol.31, No.12, 2670-2677, 2017.
(DOI: 10.1038/leu.2017.144,   PubMed: 28490812,   Elsevier: Scopus)
13. Hirokazu Miki, Shingen Nakamura, Asuka Oda, Hirofumi Tenshin, Jumpei Teramachi, Masahiro Hiasa, Ariunzaya Bat-Erdene, Yusaku Maeda, Masahiro Oura, Mamiko Takahashi, Masami Iwasa, Takeshi Harada, Shiroh Fujii, Kiyoe Kurahashi, Sumiko Yoshida, Kumiko Kagawa, Itsuro Endo, Aihara Kenichi, Mariko Ikuo, Kouji Itou, Koichiro Hayashi, Michihiro Nakamura and Masahiro Abe :
Effective impairment of myeloma cells and their progenitors by hyperthermia.,
Oncotarget, Vol.9, No.12, 10307-10316, 2017.
(徳島大学機関リポジトリ: 113059,   DOI: 10.18632/oncotarget.23121,   PubMed: 29535808,   Elsevier: Scopus)
14. Hirofumi Tenshin, Jumpei Teramachi, Asuka Oda, Ryota Amachi, Masahiro Hiasa, Ariunzaya Bat-Erdene, Keiichiro Watanabe, Masami Iwasa, Takeshi Harada, Shiroh Fujii, Kumiko Kagawa, Kimiko Sogabe, Shingen Nakamura, Hirokazu Miki, Kiyoe Kurahashi, Sumiko Yoshida, Kenichi Aihara, Itsuro Endo, Eiji Tanaka, Toshio Matsumoto and Masahiro Abe :
TAK1 inhibition subverts the osteoclastogenic action of TRAIL while potentiating its antimyeloma effects.,
Blood Advances, Vol.1, No.24, 2124-2137, 2017.
(徳島大学機関リポジトリ: 111724,   DOI: 10.1182/bloodadvances.2017008813,   PubMed: 29296860)
15. Morihiko Sagawa, Hiroto Ohguchi, Takeshi Harada, K. Mehmet Samur, Yu-Tzu Tai, C. Nikhil Munshi, Masahiro Kizaki, Teru Hideshima and C. Kenneth Anderson :
Ribonucleotide Reductase Catalytic Subunit M1 (RRM1) as a Novel Therapeutic Target in Multiple Myeloma,
Clinical Cancer Research, Vol.23, No.17, 5225-5237, 2017.
(DOI: 10.1158/1078-0432.CCR-17-0263,   PubMed: 28442502,   Elsevier: Scopus)
16. Ariunzaya Bat-Erdene, Hirokazu Miki, Asuko Oda, Shingen Nakamura, Jumpei Teramachi, Ryota Amachi, Hirofumi Tenshin, Masahiro Hiasa, Masami Iwasa, Takeshi Harada, Shiroh Fujii, Kimiko Sogabe, Kumiko Kagawa, Sumiko Yoshida, Itsuro Endo, Ken-ichi Aihara and Masahiro Abe :
Synergistic targeting of Sp1, a critical transcription factor for myeloma cell growth and survival, by panobinostat and proteasome inhibitors.,
Oncotarget, Vol.7, No.48, 79064-79075, 2016.
(徳島大学機関リポジトリ: 109988,   DOI: 10.18632/oncotarget.12594,   PubMed: 27738323)
17. Jana Jakubikova, Danka Cholujova, Teru Hideshima, Paulina Gronesova, Andrea Soltysova, Takeshi Harada, Jungnam Joo, Sun-Young Kong, Raphael E. Szalat, Paul G. Richardson, Nikhil C. Munshi, David M. Dorfman and Kenneth C. Anderson :
A novel 3D mesenchymal stem cell model of the multiple myeloma bone marrow niche: biologic and clinical applications,
Oncotarget, Vol.7, No.47, 77326-77341, 2016.
(徳島大学機関リポジトリ: 113971,   DOI: 10.18632/oncotarget.12643,   PubMed: 27764795,   Elsevier: Scopus)
18. Ryota Amachi, Masahiro Hiasa, Jumpei Teramachi, Takeshi Harada, Asuka Oda, Shingen Nakamura, Derek Hanson, Keiichiro Watanabe, Shiroh Fujii, Hirokazu Miki, Kumiko Kagawa, Masami Iwasa, Itsuro Endo, Takeshi Kondo, Sumiko Yoshida, Ken-ichi Aihara, Kiyoe Kurahashi, Yoshiaki Kuroda, Hideaki Horikawa, Eiji Tanaka, Masahiro Abe and Toshio Matsumoto :
A vicious cycle between acid sensing and survival signaling in myeloma cells: acid-induced epigenetic alteration.,
Oncotarget, Vol.7, No.43, 70447-70461, 2016.
(徳島大学機関リポジトリ: 113048,   DOI: 10.18632/oncotarget.11927,   PubMed: 27626482)
19. Takeshi Harada, Hirokazu Miki, Q Cui, A Oda, Ryota Amachi, Jumpei Teramachi, A Bat-Erdene, K Sogabe, M Iwasa, Shiroh Fujii, Shingen Nakamura, Kumiko Kagawa, Sumiko Yoshida, I Endo, Ken-ichi Aihara, Shuji Ozaki, Toshio Matsumoto and Masahiro Abe :
Expansion of Th1-like V9V2T cells by new-generation IMiDs, lenalidomide and pomalidomide, in combination with zoledronic acid.,
Leukemia, Vol.31, No.1, 258-262, 2016.
(DOI: 10.1038/leu.2016.273,   PubMed: 27698446)
20. Takeshi Harada, Shuji Ozaki, Asuka Oda, Daisuke Tsuji, Akishige Ikegame, Masami Iwasa, Kengo Udaka, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki, Kumiko Kagawa, Yoshiaki Kuroda, Shigeto Kawai, Kouji Itou, Hisafumi Yamada-Okabe, Toshio Matsumoto and Masahiro Abe :
Combination with a Defucosylated Anti-HM1.24 Monoclonal Antibody plus Lenalidomide Induces Marked ADCC against Myeloma Cells and Their Progenitors,
PLoS ONE, Vol.8, No.12, e83905, 2013.
(徳島大学機関リポジトリ: 106068,   DOI: 10.1371/journal.pone.0083905,   PubMed: 24386306,   Elsevier: Scopus)
21. Takeshi Harada, Shuji Ozaki, Asuka Oda, Shiro Fujii, Shingen Nakamura, Hirokazu Miki, Kumiko Kagawa, Kyoko Takeuchi, Toshio Matsumoto and Masahiro Abe :
Association of Th1 and Th2 cytokines with transient inflammatory reaction during lenalidomide plus dexamethasone therapy in multiple myeloma.,
International Journal of Hematology, Vol.97, No.6, 743-748, 2013.
(DOI: 10.1007/s12185-013-1321-0,   PubMed: 23609417,   Elsevier: Scopus)

総説・解説:

1. Takeshi Harada, Teru Hideshima and Kenneth C. Anderson :
Histone deacetylase inhibitors in multiple myeloma: from bench to bedside,
International Journal of Hematology, Vol.104, No.3, 300-309, Sep. 2016.
(DOI: 10.1007/s12185-016-2008-0,   PubMed: 27099225)

国際会議:

1. Takeshi Harada, Asuka Oda, Hiroto Ohguchi, Yohann Grondin, Hirofumi Tenshin, Masahiro Hiasa, Jumpei Teramachi, Masahiro Oura, Kimiko Sogabe, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki, Hirokazu Miki, Kumiko Kagawa, Shuji Ozaki, Teru Hideshima, Kenneth C. Anderson and Masahiro Abe :
Novel therapeutic rationale for targeting HDAC1 and PIM2 in multiple myeloma,
61th ASH Annual Meeting & Exposition, Orlando, Dec. 2019.
(DOI: 10.1182/blood-2019-127679)
2. Hirofumi Tenshin, Jumpei Teramachi, Masahiro Hiasa, Asuka Oda, Ashtar Mohannad, Kotaro Tanimoto, Soh Shimizu, Takeshi Harada, Masahiro Oura, Kimiko Sogabe, Itsuro Endo, Eiji Tanaka, Toshio Matsumoto and Masahiro Abe :
The role of NLRP3 inflammasome activation in joint inflammation and destruction in rheumatoid arthritis: novel therapeutic approaches with TAK1 inhibition.,
29th Australian and New Zealand Bone and Mineral Society Annual Scientific Meeting, Oct. 2019.
3. Jumpei Teramachi, Shimizu So, Hirofumi Tenshin, Bat-Erdene Ariunzaya, Masahiro Hiasa, Oda Asuka, Takeshi Harada, Ashter Mohannad, Kotaro Tanimoto, Itsuro Endo, Toshio Matsumoto, Eiji Tanaka and Masahiro Abe :
A progressive auto-amplification loop in TAK1 expression and activation in MM cells.,
American Society for Bone and Mineral Society Annual meeting 2019, Orlando, Florida, USA., Sep. 2019.
4. Hirofumi Tenshin, Jumpei Teramachi, Masahiro Hiasa, Asuka Oda, Ashtar Mohannad, Kotaro Tanimoto, Masami Iwasa, Bat-Erdene Ariunzaya, Takeshi Harada, Itsuro Endo, Eiji Tanaka, Toshio Matsumoto and Masahiro Abe :
TAK1 inhibition effectively alleviates joint inflammation as well as bone destruction in rheumatoid arthritis: Suppression of NLRP3 inflammasome-mediated inflammation and osteoclastic bone resorption,
American Society for Bone and Mineral Society Annual meeting 2019, Orlando, Florida, USA,, Sep. 2019.
5. Jumpei Teramachi, Soh Shimizu, Hirofumi Tenshin, Bat-Erdene Ariunzaya, Masahiro Hiasa, Kotaro Tanimoto, Oda Asuka, Takeshi Harada, Mohannad Ashtar, Kotaro Tanimoto, Itsuro Endo, Toshio Matsumoto, Eiji Tanaka and Masahiro Abe :
A progressive auto-amplification loop in TAK1 expression and activation in MM cells.,
ASBMR 2019,, Orlando, Florida, USA., Sep. 2019.
6. Hirofumi Tenshin, Jumpei Teramachi, Masahiro Hiasa, Oda Asuka, Ashtar Mohannad, Kotaro Tanimoto, Masami Iwasa, Bat-Erdene Ariunzaya, Takeshi Harada, Itsuro Endo, Eiji Tanaka, Toshio Matsumoto and Masahiro Abe :
TAK1 inhibition effectively alleviates joint inflammation as well as bone destruction in rheumatoid arthritis: Suppression of NLRP3 inflammasome-mediated inflammation and osteoclastic bone resorption.,
ASBMR 2019,, Orlando, Florida, USA., Sep. 2019.
7. Takeshi Harada, Asuka Oda, Hirofumi Tenshin, Jumpei Teramachi, Masahiro Oura, Kimiko Sogabe, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki, Kumiko Kagawa, Shuji Ozaki, Teru Hideshima, C. Kenneth Anderson and Masahiro Abe :
Targeting myeloma metabolisms regulated by HDAC1-IRF4 axis can be a novel therapeutic strategy,
17th International Myeloma Workshop, Sep. 2019.
8. Mohannad Ashtar, Hirofumi Tenshin, Jumpei Teramachi, Masahiro Hiasa, Kotaro Tanimoto, Oda Asuka, Iwasa Masami, Takeshi Harada, Bat-Erdene Ariunzaya, Kimiko Sogabe, Masahiro Oura, Shiroh Fujii, Kumiko Kagawa, Shingen Nakamura, Hirokazu Miki, Toshio Matsumoto, Masahiro Abe and Eiji Tanaka :
Peri-implantitis and the role of Febuxostat in osteoclast differentiation.,
AEEDC Dubai World Orthodontic Conference, Dubai, UAE, Feb. 2019.
9. Takeshi Harada, Asuka Oda, Yohann Grondin, Jumpei Teramachi, Ariunzaya Bat-Erdene, Masami Iwasa, Masahiro Oura, Shingen Nakamura, Kumiko Kagawa, Yasunobu Okamoto, Kimiko Sogabe, Shiroh Fujii, Hirokazu Miki, Shuji Ozaki, Teru Hideshima, Kenneth C. Anderson and Masahiro Abe :
The critical role of the HDAC1-IRF4-Pim-2 axis in myeloma cell growth and survival: therapeutic impacts of targeting the HDAC1-IRF4-Pim-2 axis,
60th ASH Annual Meeting & Exposition, San Diego, Dec. 2018.
10. Shingen Nakamura, Hirokazu Miki, Ariunzaya Bat-Erdene, Yasunobu Okamoto, Kimiko Sogabe, Masahiro Oura, Mamiko Takahashi, Masami Iwasa, Takeshi Harada, Shiroh Fujii, Kumiko Kagawa and Masahiro Abe :
Alteration of muscle mass after chemotherapy in patients with newly diagnosed multiple myeloma.,
Esmo asia 2018, Nov. 2018.
11. Jumpei Teramachi, Hirofumi Tenshin, Masahiro Hiasa, Oda Asuka, Bat-Erdene Ariunzaya, Takeshi Harada, Shingen Nakamura, Hirokazu Miki, Itsuro Endo, Toshio Matsumoto and Masahiro Abe :
Disruption of a progressive vicious cycle between myeloma tumor growth and bone destruction by TAK1 inhibition,
ASBMR 2018 Annual Meeting, Montreal, Sep. 2018.
12. Hirofumi Tenshin, Jumpei Teramachi, Masahiro Hiasa, Oda Asuka, Ashtar Mohannad, Kotaro Tanimoto, Iwasa Masami, Bat-Erdene Ariunzaya, Takeshi Harada, Shingen Nakamura, Hirokazu Miki, Itsuro Endo, Eiji Tanaka, Toshio Matsumoto and Masahiro Abe :
Opposite effects of TRAIL on the Sp-1-c-FLIP survival pathway in myeloma cells and osteoclasts.,
ASBMR 2018 Annual Meeting, Montreal, Sep. 2018.
13. Takeshi Harada, Oda Asuka, Jumpei Teramachi, Bat-Erdene Ariunzaya, Iwasa Masami, Oura Masahiro, Shingen Nakamura, Kumiko Kagawa, Okamoto Yasunobu, Kimiko Sogabe, Shiroh Fujii, Hirokazu Miki, Hideshima Teru, Anderson C. Kenneth and Masahiro Abe :
Selective inhibition of class-I HDAC induces myeloma cell death through targeting IRF4-Pim-2 axis,
The 9th JSH International Symposium 2018 in Kyoto, Jul. 2018.
14. Jumpei Teramachi, Hirofumi Tenshin, Masahiro Hiasa, Oda Asuka, Takeshi Harada, Shingen Nakamura, Hirokazu Miki, Tatsuji Haneji, Itsuro Endo, Toshio Matsumoto and Masahiro Abe :
Therapeutic impact of TAK1 inhibition on myeloma tumor progression and bone destruction,
8th International Workshop on Advances in the Molecular Pharmacology and Therapeutics of Bone and other Musculoskeletal Diseases and Cancer and Bone Society 2018 Meeting, Oxford, Jun. 2018.
15. Jumpei Teramachi, Masahiro Hiasa, Oda Asuka, Hirofumi Tenshin, Ryota Amachi, Takeshi Harada, Shingen Nakamura, Hirokazu Miki, Itsuro Endo, Tatsuji Haneji, Toshio Matsumoto and Masahiro Abe :
TAK1 inhibition impairs myeloma cell-bone marrow interaction to reduce myeloma tumor growth and bone destruction,
American Society for Bone and Mineral Research (ASBMR) 2017 Annual Meeting, Denver, Sep. 2017.
16. Jumpei Teramachi, Masahiro Hiasa, Oda Asuka, Hirofumi Tenshin, Ryota Amachi, Takeshi Harada, Shingen Nakamura, Hirokazu Miki, Itsuro Endo, Tatsuji Haneji, Toshio Matsumoto and Masahiro Abe :
Therapeutic impact of TAK1 inhibition on myeloma tumor progression and bone destruction,
International Society for Experimental Hematology 46th Annual Scientific Meeting, Frankfurt, Aug. 2017.
17. Jumpei Teramachi, Masahiro Hiasa, Oda Asuka, Hirofumi Tenshin, Ryota Amachi, Takeshi Harada, Shingen Nakamura, Hirokazu Miki, Itsuro Endo, Akihito Yamamoto, Tatsuji Haneji, Toshio Matsumoto and Masahiro Abe :
Therapeutic impact of TAK1 inhibition on myeloma tumor progression and bone destruction,
Cancer and Bone Society Conference 2017, Indianapolis, May 2017.

国内講演発表:

1. 天眞 寛文, 寺町 順平, 日浅 雅博, 谷本 幸多朗, ASHTAR MOHANNAD, Bat-Erdene Ariunzaya, 岩佐 昌美, 原田 武志, 中村 信元, 三木 浩和, 遠藤 逸朗, 田中 栄二, 松本 俊夫, 安倍 正博 :
TAK1阻害は関節リウマチにおけるNLRP3インフラマソーム誘導性の炎症および骨破壊を抑制する,
日本骨代謝学会学術集会プログラム抄録集, 2019年10月.
2. 谷本 幸多朗, 日浅 雅博, 岩浅 亮彦, 天眞 寛文, 寺町 順平, ASHTAR MOHANNAD, 岩佐 昌美, 小田 明日香, 曾我部 公子, 大浦 雅博, 原田 武志, 中村 信元, 三木 浩和, 遠藤 逸朗, 田中 栄二, 松本 俊夫, 安倍 正博 :
不動性骨吸収の亢進は骨髄内の骨髄腫進展を促進させる.,
日本骨代謝学会学術集会プログラム抄録集, 2019年10月.
3. 原田 武志 :
多発性骨髄腫におけるHDACアイソフォームの役割とその選択的阻害による治療法の開発,
第81回日本血液学会学術集会, 2019年10月.
4. 天眞 寛文, 寺町 順平, 日浅 雅博, 谷本 幸多朗, ASHTAR MOHANNAD, Ariunzaya Bat-Erdene, 岩佐 昌美, 原田 武志, 中村 信元, 三木 浩和, 遠藤 逸朗, 田中 栄二, 松本 俊夫, 安倍 正博 :
TAK1阻害は関節リウマチにおけるNLRP3インフラマソーム誘導性の炎症および骨破壊を抑制する.,
第37回日本骨代謝学会学術集会, 2019年10月.
5. 谷本 幸太朗, 日浅 雅博, 天眞 寛文, 寺町 順平, ASHTAR MOHANNAD, 岩佐 昌美, 小田 明日香, 曽我部 公子, 大浦 雅博, 原田 武志, 中村 信元, 三木 浩和, 遠藤 逸朗, 田中 栄二, 松本 俊夫, 安倍 正博 :
不動性骨吸収の亢進は骨髄内の骨髄腫進展を促進させる,
第37回日本骨代謝学会学術集会, 2019年10月.
6. Hirofumi Tenshin, Jumpei Teramachi, Masahiro Hiasa, 小田 明日香, Kotaro Tanimoto, Soh Shimizu, Ashtar Mohannad, Takeshi Harada, Eiji Tanaka, Toshio Matsumoto and Masahiro Abe :
NLRP3 inflammasome-mediated inflammation and osteoclastic bone resorption in rheumatoid arthritis : the therapeutic roles of TAK1 inhibition,
16th Meeting of Bone Biology Forum, Aug. 2019.
7. 安宅 克博, 中村 信元, 大浦 雅博, 曽我部 公子, 原田 武志, 藤井 志朗, 三木 浩和, 賀川 久美子, 西岡 安彦, 安倍 正博 :
長期にわたる血小板減少が先行した芽球性形質細胞様樹状細胞腫瘍の1例,
第120回日本内科学会四国地方会, 2019年5月.
8. 原田 武志, Oda Asuka, 天眞 寛文, 寺町 順平, 大浦 雅博, 曽我部 公子, 岩佐 昌美, 藤井 志朗, 三木 浩和, 賀川 久美子, 秀島 輝, Anderson C. Kenneth, 安倍 正博 :
The novel therapeutic strategy targeting the HDAC1-IRF4-PIM2 pathway in myeloma cells,
The 44th Annual Meeting of the Japanese Society of Myeloma, 2019年5月.
9. Jumpei Teramachi, Hirofumi Tenshin, Masahiro Hiasa, Oda Asuka, Bat-Erdene Ariunzaya, Takeshi Harada, Iwasa Masami, Shiroh Fujii, Kimiko Sogabe, Shingen Nakamura, Hirokazu Miki, Masahiro Oura, Kumiko Kagawa, Itsuro Endo, Toshio Matsumoto and Masahiro Abe :
Mechanisms of TAK1 over-activation in myeloma cells and TAK1-mediated myeloma growth and bone destruction,
第80回日本血液学会学術集会, Oct. 2018.
10. Takeshi Harada :
Roles of HDAC1 and HDAC3 as therapeutic targets against myeloma cells,
The 80th Annual Meeting of the Japanese Society of Hematology, Oct. 2018.
11. 岩佐 昌美, 原田 武志, Ariunzaya Bat-Erdene, 小田 明日香, 曽我部 公子, 大浦 雅博, 寺町 順平, 藤井 志朗, 中村 信元, 三木 浩和, 賀川 久美子, 安倍 正博 :
HDAC阻害による骨髄腫細胞のIFN-γ-STAT1- PD-L1経路の増強効果,
第80回日本血液学会学術集会, 2018年10月.
12. Ashtar Mohannad, Hirofumi Tenshin, Jumpei Teramachi, Masahiro Hiasa, Kotaro Tanimoto, Oda Asuka, Iwasa Masami, Takeshi Harada, Ariunzaya Erdene Bat, Kimiko Sogabe, Oura Masahiro, Shiroh Fujii, Kumiko Kagawa, Shingen Nakamura, Hirokazu Miki, Eiji Tanaka, Toshio Matsumoto and Masahiro Abe :
Roles of ROS in induction of bone disease and cancer treatment-induced bone loss in myeloma.,
The 80th Annual Meeting of the Japanese Society of Hematology, Oct. 2018.
13. Hirofumi Tenshin, Jumpei Teramachi, Masahiro Hiasa, Kotaro Tanimoto, Mohannad Ashtar, Ariunzaya Bat-Erdene, Iwasa Masami, Takeshi Harada, Shingen Nakamura, Hirokazu Miki, Kimiko Sogabe, Oura Masahiro, Shiroh Fujii, Kumiko Kagawa, Itsuro Endo, Eiji Tanaka, Toshio Matsumoto and Masahiro Abe :
Inverse regulation of c-FLIP-mediated survival in myeloma cells and osteoclasts by TRAIL.,
The 80th Annual Meeting of the Japanese Society of Hematology, Oct. 2018.
14. Kotaro Tanimoto, Masahiro Hiasa, Hirofumi Tenshin, Jumpei Teramachi, Oda Asuka, Mohannad Ashtar, Ariunzaya Bat-Erdene, Iwasa Masami, Kimiko Sogabe, Oura Masahiro, Takeshi Harada, Shingen Nakamura, Hirokazu Miki, Itsuro Endo, Eiji Tanaka, Toshio Matsumoto and Masahiro Abe :
Impact of denervation-induced paralysis and mechanical unloading on tumor expansion in myeloma.,
The 80th Annual Meeting of the Japanese Society of Hematology, Oct. 2018.
15. Masahiro Hiasa, Jumpei Teramachi, Hirofumi Tenshin, Kotaro Tanimoto, Ariunzaya Bat-Erdene, Mohannad Ashtar, Masami Iwasa, Takeshi Harada, Shingen Nakamura, Hirokazu Miki, Kimiko Sogabe, Oura Masahiro, Shiroh Fujii, Kumiko Kagawa, Oda Asuka, Itsuro Endo, Eiji Tanaka, Toshio Matsumoto and Masahiro Abe :
The effects of cathepsin K inhibition on osteocytes: its role in bone restoration in MM bone disease.,
The 80th Annual Meeting of the Japanese Society of Hematology, Oct. 2018.
16. 日浅 雅博, 寺町 順平, 天眞 寛文, 谷本 幸多朗, ASHTAR MOHANNAD, Ariunzaya Bat-Erdene, 岩佐 昌美, 原田 武志, 中村 信元, 三木 浩和, 遠藤 逸朗, 田中 栄二, 松本 俊夫, 安倍 正博 :
カテプシンK阻害による多発性骨髄腫骨病変部の骨量 回復プロセスにおける骨細胞の役割.,
第36回日本骨代謝学会学術集会, 2018年7月.
17. 天眞 寛文, 寺町 順平, 日浅 雅博, 谷本 幸多朗, ASHTAR MOHANNAD, Ariunzaya Bat-Erdene, 岩佐 昌美, 原田 武志, 中村 信元, 三木 浩和, 遠藤 逸朗, 田中 栄二, 松本 俊夫, 安倍 正博 :
TAK1阻害はTRAILによる破骨細胞活性化作用を遮断 させると同時にTRAILの抗骨髄腫作用を増強する,
第36回日本骨代謝学会学術集会, 2018年7月.
18. 天眞 寛文, 寺町 順平, 日浅 雅博, 小田 明日香, 谷本 幸多朗, ASHTAR MOHANNAD, Ariunzaya Bat-Erdene, 岩佐 昌美, 原田 武志, 中村 信元, 三木 浩和, 遠藤 逸朗, 田中 栄二, 松本 俊夫, 安倍 正博 :
TAK1による破骨細胞に対するTRAILの生存・細胞死シグナル制御機構.,
第4回日本骨免疫学会, 2018年6月.
19. 谷本 幸多朗, 日浅 雅博, 天眞 寛文, 寺町 順平, 小田 明日香, ASHTAR MOHANNAD, Ariunzaya Bat-Erdene, 岩佐 昌美, 曽我部 公子, 大浦 雅弘, 原田 武志, 中村 信元, 三木 浩和, 遠藤 逸朗, 田中 栄二, 松本 俊夫, 安倍 正博 :
神経切断による麻痺と免荷の骨髄腫の進展への影響.,
第4回日本骨免疫学会, 2018年6月.
20. 岩佐 昌美, 原田 武志, Ariunzaya Bat-Erdene, 小田 明日香, 前田 悠作, 高橋 真美子, 大浦 雅博, 寺町 順平, 藤井 志朗, 中村 信元, 三木 浩和, 賀川 久美子, 安倍 正博 :
パノビスタットによる骨髄腫細胞のIFN-γ-STAT1- PD-L1経路の増強,
The 43rd Annual Meeting of the Japanese Society of Myeloma, 2018年5月.
21. 原田 武志, Oda Asuka, 寺町 順平, Bat-Erdene Ariunzaya, 岩佐 昌美, Maeda Yusaku, 中村 信元, Oura Masahiro, 藤井 志朗, 三木 浩和, 賀川 久美子, Hideshima Teru, Anderson C. Kenneth, 安倍 正博 :
HDAC1/3 inhibition disrupts the IRF4-Pim-2 pathway to induce effective myeloma cell death,
The 43rd Annual Meeting of the Japanese Society of Myeloma, 2018年5月.
22. Jumpei Teramachi, Masahiro Hiasa, Oda Asuka, Hirofumi Tenshin, Ryota Amachi, Takeshi Harada, Shingen Nakamura, Masami Iwasa, Masahiro Oura, Yusaku Maeda, Shiroh Fujii, Kumiko Kagawa, Hirokazu Miki, Itsuro Endo, Toshio Matsumoto and Masahiro Abe :
Disruption of myeloma cell-bone marrow interaction by TAK-1 inhibition,
第80回日本血液学会学術集会, Oct. 2017.
23. Takeshi Harada, Ohguchi Hiroto, Grondin Yohann, Kikuchi Shohei, Sagawa Morihiko, Tai Yu-Tzu, Mazitschek Ralph, Hideshima Teru and Anderson C. Kenneth :
HDAC3 regulates DNMT1 expression in multiple myeloma: therapeutic implications,
The 79th Annual Meeting of the Japanese Society of Hematology, Oct. 2017.
24. Jumpei Teramachi, Masahiro Hiasa, Oda Asuka, Hirofumi Tenshin, Ryota Amachi, Takeshi Harada, Shingen Nakamura, Masami Iwasa, Masahiro Ohhra, Yusaku Maeda, Shiroh Fujii, Kumiko Kagawa, Hirokazu Miki, Itsuro Endo, Toshio Matsumoto and Masahiro Abe :
Disruption of myeloma cell-bone marrow interaction by TAK-1 inhibition,
第80回日本血液学会学術集会, Oct. 2017.
25. 寺町 順平, 森 裕史, 越智 保夫, 天知 良太, 小田 明日香, 日浅 雅博, 原田 武志, 藤井 志朗, 中村 信元, 三木 浩和, 賀川 久美子, 遠藤 逸朗, 田中 栄二, 松本 俊夫, 安倍 正博 :
Potent induction of bone formation by anti-resorptive cathepsin K inhibitor in myeloma.,
第77回日本血液学会学術集会,, 2016年10月.

科学研究費補助金 (KAKEN Grants Database @ NII.ac.jp)

  • HTLV-1感染伝播、ATLの発症/悪性化を阻止しうる新規治療の開発 (研究課題/領域番号: 20K17402 )
  • 骨髄腫細胞のメタボリックシフトに及ぼすHDAC1/3の役割と新規治療戦略の創出 (研究課題/領域番号: 18K16118 )
  • 研究者番号(10618359)による検索